Akorn, Inc. Announces FDA Approval Of Diclofenac Sodium Ophthalmic Solution 0.1% (Medical News Today)
Akorn, Inc. (NASDAQ: AKRX) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Akorn's Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Ophthalmic Solution, 0.1%. Diclofenac Sodium Ophthalmic Solution is a non-steroidal anti-inflammatory agent used to treat cataract and refractive surgery patients.

Confidence in FDA Hits New Low, According to WSJ.com/Harris Interactive Study (Centre Daily Times)
Majorities of U.S. adults give negative ratings for the Food and Drug Administration (FDA) on a number of measures, such as ensuring new drugs come to market quickly (60% negative) and managing recalls or withdrawals when safety concerns arise (53%). The perception that the FDA does a good job ensuring the safety and efficacy of new prescription drugs (35% positive) has declined from 45 percent ...